<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">Iron overload</z:e> is a significant clinical problem in patients with severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> or other transfusion-dependent <z:hpo ids='HP_0005528'>bone marrow failure</z:hpo> diseases </plain></SENT>
<SENT sid="1" pm="."><plain>Iron chelation therapy is more readily available owing to the recent introduction of oral iron <z:chebi fb="0" ids="38161">chelators</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>We describe 2 cases of children with severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> and related transfusional <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e> who received iron chelation therapy with oral <z:chebi fb="0" ids="49005">deferasirox</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>Our patients experienced restoration of trilineage hematopoiesis after the administration of <z:chebi fb="0" ids="49005">deferasirox</z:chebi> along with the reduction in ferritin levels, and subsequently became transfusion-free </plain></SENT>
<SENT sid="4" pm="."><plain>Our report raises the possibility of potential benefit on hematopoiesis from iron chelation therapy and warrants furthermore investigations </plain></SENT>
</text></document>